Detailed description page of ThPDB2

This page displays user query in tabular form.

10447 details
Primary information
ID10447
Therapeutic IDTh1079
Protein NameSerum albumin
Sequence>Th1079_Serum_albumin MKWVTFISLLFLFSSAYSRGVFRRDAHKSEVAHRFKDLGEENFKALVLIAFAQYLQQCPFEDHVKLVNEVTEFAKTCVADESAENCDKSLHTLFGDKLCTVATLRETYGEMADCCAKQEPERNECFLQHKDDNPNLPRLVRPEVDVMCTAFHDNEETFLKKYLYEIARRHPYFYAPELLFFAKRYKAAFTECCQAADKAACLLPKLDELRDEGKASSAKQRLKCASLQKFGERAFKAWAVARLSQRFPKAEFAEVSKLVTDLTKVHTECCHGDLLECADDRADLAKYICENQDSISSKLKECCEKPLLEKSHCIAEVENDEMPADLPSLAADFVESKDVCKNYAEAKDVFLGMFLYEYARRHPDYSVVLLLRLAKTYETTLEKCCAAADPHECYAKVFDEFKPLVEEPQNLIKQNCELFEQLGEYKFQNALLVRYTKKVPQVSTPTLVEVSRNLGKVGSKCCKHPEAKRMPCAEDYLSVVLNQLCVLHEKTPVSDRVTKCCTESLVNRRPCFSALEVDETYVPKEFNAETFTFHADICTLSEKERQIKKQTALVELVKHKPKATKEQLKAVMDDFAAFVEKCCKADDKETCFAEEGKKLVAASQAALGL
Molecular Weight66472.2
Chemical FormulaC2936H4624N786O889S41
Isoelectric Point5.67
Hydrophobicity-0.395
Melting point62
Half-lifeNA
DescriptionSuspension of microspheres of human serum albumin with perflutren. Perflutren is a highly fluorinated small molecule, used to enhance contrast for ultrasound imaging procedures
Indication/DiseaseFor treatment of severe blood loss, hypervolemia, hypoproteinemia.
PharmacodynamicsSerum albumin is a soluble, monomeric protein necessary for maintaining and regulating the colloidal osmotic pressure of blood. It is used to increase the circulating plasma volume, thereby reducing hemoconcentration and blood viscosity. Also used as a transport protein that binds naturally occurring, therapeutic and toxic materials in circulation.
Mechanism of ActionSerum albumin acts as a high molecular weight, very soluble osmolyte. Serum albumin also acts as a protein drug carrier in plasma, and transports hemin, steroids, thyroid hormones and fatty acids. It binds many other substances, such as unconjugated bilirubin, calcium ions, and other fat soluble hormones.
ToxicityIn general, human albumin solutions are well-tolerated and no specific, clinically relevant alterations in organ function or coagulopathy have been substantiated .The most common adverse reactions are rigors, hypotension, tachycardia with increased heart rate, fever, chills, nausea, vomiting, dyspnea and/or bronchospasm, skin rash/pruritus. Stop the infusion immediately if anaphylaxis, with or without shock is observed . Hypervolemia may occur if the dosage and rate of infusion are not adjusted to the volume status of the patient. When clinical signs of cardiovascular overload occur (headache, dyspnea, jugular venous distention, increased blood pressure), the infusion must be slowed or stopped immediately.
MetabolismNA
AbsorptionNA
Albumin is distributed throughout the extracellular space and more than 60% of the body albumin pool is located in the extravascular fluid space .In healthy adults, less than 10% of infused albumin leaves the intravascular compartment during the first 2 hours following infusion of albumin
ClearanceNA
CategoriesSerum substitutes
Patents NumberUS5558094
Date of Issue24-Sep-1996
Date of Expiry19-Jan-2016
Drug InteractionNA
TargetNA
Brand NameOptison
CompanyGE Healthcare
Brand DescriptionGE Healthcare
Prescribed ForNA
Chemical NameNA
FormulationOptison (Perflutren Protein-Type A Microspheres Injectable Suspension, USP) is available in a carton of five 3 mL fills in single use 3 mL vials. Each mL of Optison contains 5.0-8.0×108 protein-type A microspheres, 10 mg Albumin Human, USP, 0.22 ± 0.11 mg/mL perflutren, 0.2 mg N-acetyltryptophan, and 0.12 mg caprylic acid in 0.9% aqueous sodium chloride. The headspace of the vial is filled with perflutren gas. The pH is adjusted to 6.4-7.4. The protein in the microsphere shell makes up approximately 5-7% (w/w) of the total protein in the liquid.
Physical Appearance NA
Route of AdministrationIntravenous
Recommended DosageNA
ContraindicationRight-to-left, bi-directional, or transient right-to-left cardiac shunts, Hypersensitivity to perflutren, blood, blood products or albumin. Do not administer Optison by intra-arterial injection. This product contains albumin, a derivative of human blood. Based on effective donor screening and product manufacturing processes, it carries an extremely remote risk for transmission of viral disease. A theoretical risk for transmission of Creutzfeldt-Jakob disease (CJD) also is considered extremely remote. No cases of transmission of viral disease or CJD have ever been identified for albumin.
Side EffectsNA
Useful Link 1NA
Useful Link 2NA
RemarksNA